| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
We analyzed genetic abnormalities in the patients with therapy-related myeloid neoplasms (t-MN), and found that gene abnormalities of RUNX1 orMLL gene were the most common molecular abnormalities in t-MN after acute promyelocytic leukemia treated with VP16. VP16-treated cells showed rearrangement bands in both RUNX1 and MLL genes, suggesting that it may result in subsequent development of t-MN. Furthermore, we verified that RUNX1 mutant collaborates with BMI1 overexpression in the development of t-MDS/AML.
|
